Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

0.2180 +0.0112 (+5.42%)
Streaming Delayed Price Updated: 10:24 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
From Mainz BioMed NV
Via GlobeNewswire
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why MEI Pharma Shares Are Trading Lower By Around 35%; Here Are 20 Stocks Moving Premarket
Gainers Starry Group Holdings, Inc. (NYSE: STRY) shares rose 43.5% to $0.2011 in pre-market trading after dipping more than 20% on Monday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! We're starting off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! 
Via InvestorPlace
Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leader 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Provides Third Quarter 2022 Update
From Mainz BioMed NV
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022
Upgrades 
Via Benzinga
Mainz Biomed’s Colorectal And Pancreatic Cancer Screening Diagnostics Are More Than Life Savers, They Are Significant Value Drivers ($MYNZ)
Via AB Newswire
Mainz Biomed Best-In-Class Colorectal Cancer Screening Diagnostics Expand International Presence, Targets Billion Dollar Market Opportunities ($MYNZ)
Via AB Newswire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
Mainz Biomed Best-In-Class Cancer Screening Diagnostics Tap Into Billion Dollar Market Opportunities ($MYNZ)
Via AB Newswire
Mainz Biomed Stock Higher; Market Expansion Of Its Best-In-Class Cancer Diagnostics Power The Move ($MYNZ)
Via AB Newswire
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed (NASDAQ:MYNZ) could storm Wall Street with its molecular genetic diagnostic solutions for life-threatening conditions
Via AB Newswire
Exposures Product Safety
Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer Screening Diagnostics ($MYNZ)
Via AB Newswire
Biotech Stocks could be recession proof as bond market plunges (MYNZ, RVNC, AXSM, ABBV)
Via AB Newswire
Topics Bonds Economy Stocks
Exposures Debt Markets Economy Interest Rates
Why GreenBox POS Is Trading Higher By Around 72%, Here Are 70 Stocks Moving In Tuesday's Mid-Day Session
Gainers GreenBox POS (NASDAQ: GBOX) shares jumped 72.4% to $2.19 as the company reported better-than-expected Q2 sales. 
Via Benzinga
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday
Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Nu Holdings, Ally Financial And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) shares rose 17.5% to $4.10 in pre-market trading after the company said Q2 sales results were up year over year and raised FY22 sales guidance above... 
Via Benzinga
Why IZEA Worldwide Shares Are Trading Higher By Over 30%: Here Are 37 Stocks Moving Premarket
Gainers IZEA Worldwide, Inc. (NASDAQ: IZEA) shares rose 30.8% to $1.19 in pre-market trading after the company reported a second-quarter revenue increase of 96% year-over-year to $12.58 million,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.